Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Obesity Drug Setback

Overview

• Investors seeking to serve as lead plaintiff must move the court by January 16, 2026.
• The case covers purchasers of Skye securities from November 4, 2024 through October 3, 2025.
• Plaintiffs point to October 6, 2025 topline data showing nimacimab failed its primary weight‑loss endpoint, after which the stock fell about 60% to close at $1.90.
• Multiple firms, including Johnson Fistel, Rosen Law Firm, Berger Montague, and Faruqi & Faruqi, are soliciting shareholders to join the litigation.
• No class has been certified at this stage, and the complaint seeks recovery of investor losses under federal securities laws.